Synchrony Financial (NYSE:SYF – Get Rating) posted its quarterly earnings results on Monday. The financial services provider reported $1.26 EPS for the quarter, beating the consensus estimate of $1.12 by $0.14, RTT News reports. Synchrony Financial had a net margin of 17.51% and a return on equity of 24.07%. The business had revenue of $4.74 billion during the quarter, compared to analyst estimates of $4.04 billion. During the same quarter in the previous year, the business posted $1.48 EPS.
Synchrony Financial Price Performance
NYSE SYF opened at $35.37 on Wednesday. The stock’s fifty day moving average price is $34.25 and its 200 day moving average price is $33.43. Synchrony Financial has a 1 year low of $27.22 and a 1 year high of $47.05. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.20 and a quick ratio of 1.21. The company has a market cap of $15.94 billion, a price-to-earnings ratio of 5.60, a PEG ratio of 0.98 and a beta of 1.61.
Insiders Place Their Bets
In related news, insider Carol Juel sold 31,303 shares of the stock in a transaction that occurred on Friday, November 11th. The shares were sold at an average price of $40.00, for a total value of $1,252,120.00. Following the transaction, the insider now owns 55,929 shares in the company, valued at approximately $2,237,160. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, insider Carol Juel sold 31,303 shares of the business’s stock in a transaction on Friday, November 11th. The shares were sold at an average price of $40.00, for a total transaction of $1,252,120.00. Following the completion of the transaction, the insider now directly owns 55,929 shares in the company, valued at $2,237,160. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Margaret M. Keane sold 68,369 shares of the stock in a transaction dated Monday, November 28th. The stock was sold at an average price of $36.50, for a total value of $2,495,468.50. Following the sale, the insider now directly owns 762,786 shares in the company, valued at $27,841,689. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Analyst Ratings Changes
A number of brokerages recently commented on SYF. Barclays downgraded shares of Synchrony Financial from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $41.00 to $38.00 in a research note on Friday, January 6th. UBS Group initiated coverage on Synchrony Financial in a research note on Monday, November 21st. They set a “neutral” rating and a $42.00 price objective for the company. Wells Fargo & Company lifted their target price on Synchrony Financial from $32.00 to $37.00 and gave the company an “equal weight” rating in a research note on Thursday, December 15th. Morgan Stanley increased their price target on shares of Synchrony Financial from $29.00 to $31.00 and gave the company an “underweight” rating in a research report on Tuesday. Finally, Citigroup lifted their price objective on shares of Synchrony Financial from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $39.27.
About Synchrony Financial
Synchrony Financial engages in the provision of consumer financial services. It operates through three sales platforms: Retail Card, Payment Solutions, and CareCredit. The Retail Card platform is a provider of private label credit cards, and also provides Dual Cards and small-and medium-sized business credit products.
- Get a free copy of the StockNews.com research report on Synchrony Financial (SYF)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Synchrony Financial Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synchrony Financial and related companies with MarketBeat.com's FREE daily email newsletter.